Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

05 Ottobre 2026 · mostra note

Podcasts

INFORMAZIONI SU QUESTO EPISODIO

Featuring an interview with Dr L Elizabeth Budde, including the following topics:

Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)
Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)
Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)
Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)

CME information and select publications

Medicina

Istruzione

Salute e benessere

Medicina

Scienza e medicina

Inglese

Stati Uniti

UsaAPIper recuperare questo episodio inJSON

IN QUESTO EPISODIO

lisocabtagene maraleucel

# polatuzumab vedotin

elizabeth budde

Modifica queste etichette

MOSTRA NOTE 🔗

00:00:00Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy

00:07:35Management of BsAb-induced cytokine release syndrome and other toxicities

00:17:30Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study

00:23:18Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting

00:32:52Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting

00:37:35Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin

TRASCRIZIONE 🔗

Are you the producer of this podcast? Add a podcast transcript

Need Audio-to-Text? Transcribe with Listen411 in Just 60 Seconds

CERCA TRA GLI EPISODI PASSATI

Cerca gli episodi passati di Oncology Today with Dr Neil Love.

Incorpora questa barra di ricerca nel tuo sito web

ALTRI EPISODI IN QUESTO PODCAST

Ovarian and Endometrial Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

30 Settembre 2026

Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) Ovarian Cancer (2:22) Endometrial Cancer (37:48) CME information and select publications